Multiple myeloma: symptoms, diagnosis, treatment, monitoring and safety

Multiple myeloma, also called myeloma, is a blood cancer arising from plasma cells in bone marrow. It can affect bones, kidneys and infection defenses. Specialist care aims to control the disease and its complications; the diagnosis, general health and treatment history determine the plan. NHS: myeloma definition.

Table of contents

• Evidence summary
• What multiple myeloma is: plasma cells, MGUS and related disorders
• Diagnosis and biology: proteins, marrow, imaging and myeloma-defining events
• Treatment pathways: initial care, transplant, maintenance and relapse
• Supplements and daily support: nutrition, fatigue and bone-safe activity
• What is established and uncertain: smouldering disease, newer therapies and evidence limits
• Risks and urgent symptoms: spinal problems, infection and treatment toxicity
• Interactions: steroids, blood testing, procedures and complementary products
• Who needs extra assessment: frailty, organ function, pregnancy and fertility
• Clinician-led use and follow-up: a written plan for changing disease
• Animal and laboratory evidence: mechanisms are not a human prescription
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary

Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.

What multiple myeloma is: plasma cells, MGUS and related disorders

An abnormal plasma-cell clone can produce M protein, also called paraprotein. MGUS means monoclonal gammopathy of undetermined significance and is not itself cancer. A solitary plasmacytoma is localized; additional marrow or organ disease can change its classification and care. NCI: plasma-cell neoplasm patient PDQ.

Persistent back, hip or rib pain, unusual fatigue, breathlessness, weakness, weight loss, increased thirst or urination can prompt investigation. Some people have no noticeable symptoms. These problems have many possible causes, so symptoms do not establish myeloma and reassuring symptom improvement should not replace an arranged investigation. NHS: myeloma symptoms.

The exact cause is often unknown. Risk patterns include older age, a prior MGUS diagnosis and a family history of myeloma. A risk factor does not mean someone caused their illness or will certainly develop it. A family history is useful information for the clinician; it is not a reason to start an anticancer supplement or unarranged treatment. NHS: myeloma risk factors.

Diagnosis and biology: proteins, marrow, imaging and myeloma-defining events

Abnormal plasma cells can disrupt normal blood-cell production and immune function. Protein results vary: some myelomas produce an intact immunoglobulin, others mainly light chains, while nonsecretory disease produces little or no measurable protein. These descriptions help explain why one blood measurement cannot describe every case; the team chooses markers appropriate to the disease. CUH: myeloma and protein subtypes.

Investigation can include blood and urine tests, bone-marrow sampling and imaging such as CT or MRI. These answer different questions about abnormal proteins, blood counts, organ function, the plasma cells and affected bones. Ask which result is still pending and who will explain the combined diagnosis; a scan alone does not provide every part of the assessment. NHS: myeloma investigation.

Active myeloma requires a qualifying clonal plasma-cell disorder together with a myeloma-defining event. These include attributable high calcium, kidney impairment, anemia or lytic (bone-destroying) damage, summarized as CRAB, and particular marrow, light-chain or MRI biomarkers. Smouldering myeloma lacks defining events. The criteria require specialist interpretation; absence of pain does not exclude active disease. Rajkumar: August 2026 myeloma clinical review.

Marrow aspiration collects a fluid sample; a trephine biopsy collects a small core. Sampling helps identify the abnormal cells and their pattern. Tell the team about anticoagulants, other medicines and allergies beforehand. The service determines preparation and bleeding precautions; use its instructions rather than a generic online medicine-hold schedule. CUH: marrow aspiration and core biopsy.

Treatment pathways: initial care, transplant, maintenance and relapse

A specialist plan may combine anticancer medicines, steroids and targeted treatments. Selected people receive high-dose therapy with stem-cell support; radiation or other procedures may address particular bone problems. Some people initially need monitoring rather than immediate treatment. The choice depends on disease features, symptoms, overall health and whether this is a new diagnosis or relapse. NHS: myeloma treatment.

Myeloma staging uses markers such as beta-2-microglobulin, albumin, lactate dehydrogenase (LDH) and cytogenetics; marrow fluorescence in situ hybridization (FISH) identifies chromosome changes. This differs from a solid tumor’s size-and-spread stage. The specialist considers stage alongside health, organ damage and previous response; it cannot alone predict an individual lifespan. NCI: professional plasma-cell PDQ.

Common combinations include a proteasome inhibitor such as bortezomib, an immunomodulatory medicine such as lenalidomide, dexamethasone and sometimes a monoclonal antibody. Fitness and disease features influence selection; this list is not a personal regimen. NCI: professional plasma-cell PDQ.

An autologous transplant returns the person’s own blood-forming stem cells after intensive treatment; it supports recovery of blood-cell production rather than being a stand-alone injection that removes myeloma. A donor transplant is different and has additional risks such as graft-versus-host disease. Preparation, recovery and suitability belong to an experienced transplant service. NCI: blood stem-cell transplantation.

After initial care, some people have maintenance treatment or a monitoring phase. Follow-up can combine symptom review, medicine review and blood results, with a consultant retaining responsibility. Selected services offer nurse-led telephone appointments, while changing problems can require in-person review. Maintenance is still treatment; monitoring is still planned care, with an individualized contact and testing schedule. CUH: selected myeloma telephone follow-up.

If myeloma relapses after treatment, further care may be needed. Discuss the previous medicines, response and side effects with the team when planning another option. NHS: myeloma treatment.

Supplements and daily support: nutrition, fatigue and bone-safe activity

Reduced appetite, nausea or other treatment effects can make it difficult to eat enough and maintain weight. Report declining intake rather than assuming it is inevitable. A dietitian can help adapt food and nutritional support to symptoms and medical needs. A restrictive anticancer diet should not replace a plan that protects adequate intake. NCI: nutrition and appetite.

Fatigue deserves assessment because cancer, treatment, sleep difficulties, pain and other medical problems can contribute. Discuss which activities are safe and how to balance movement and rest. Use the team’s advice when bone lesions, fractures or other limitations make usual exercise unsuitable; there is no universal lifting or training prescription in this guide. NCI: cancer fatigue.

Palliative care can help with pain, other symptoms, emotional stress and practical decisions alongside disease-directed treatment. It does not require giving up anticancer care. Ask for support when symptoms are restricting daily life, even while a treatment is working or the team is planning the next option. NCI: palliative care.

No supplement replacement for myeloma treatment is established here. Complementary products can interact with care and should be discussed with the team. Correcting a deficiency can address nutrition without establishing anticancer efficacy. Avoid claims of a natural cure or guaranteed prevention of relapse. NCCIH: cancer and complementary approaches.

What is established and uncertain: smouldering disease, newer therapies and evidence limits

The US FDA approved daratumumab with hyaluronidase-fihj for adults with high-risk smouldering myeloma on 6 November 2025. This does not cover every smouldering diagnosis or establish worldwide access. Earlier blanket no-treatment statements are incomplete; discuss the exact diagnosis and risk category. FDA: November 2025 high-risk smouldering approval.

CAR-T treatment collects T cells and modifies them to recognize a cancer target before returning them under specialist supervision. It is a distinct process from an autologous blood stem-cell transplant. Availability depends on the exact product and indication, previous treatment and clinical assessment; it is not a routine option for every person with newly diagnosed myeloma. NCI: T-cell transfer and CAR-T.

A clinical trial may study a new treatment, combination or timing of care. Participation requires eligibility, informed consent and monitoring, and cannot promise personal benefit. Ask how the research differs from available usual care, what additional visits or risks it creates, which sponsor supports it and what happens if you stop participating. NCI: clinical trial participation.

This guide attributes clinical pathways to the reviewed sources. It does not award an independent efficacy verdict to a manufacturer-funded trial, or rank drugs by promotional response claims. Diagnosis, disease control, symptoms, quality of life and survival are different questions; one reported measure should not be silently substituted for another.

Risks and urgent symptoms: spinal problems, infection and treatment toxicity

During cancer treatment, fever, chills or other infection signs need immediate contact with the treating service under its emergency instructions. Low white-cell counts can make infection dangerous. Do not wait for the next routine visit or mask a possible fever with a new medicine before seeking advice; tell the service about all symptoms and recent treatment. NCI: infection during treatment.

Bone-protective medicines such as bisphosphonates and denosumab can cause osteonecrosis of the jaw. Dental assessment and communication between the cancer team and dentist are important. Report jaw pain, exposed bone, swelling, loose teeth or poor healing straight away. Do not independently stop treatment or arrange dental surgery without explaining the cancer medicines. CRUK: bone-drug jaw complications.

Dexamethasone can affect sleep, mood and blood sugar, and can increase infection-related concerns. Report troublesome effects promptly; symptoms need medical interpretation rather than an assumed cause. Severe breathing or allergic symptoms, vomiting blood or thoughts of self-harm require immediate emergency help. Treatment-specific advice takes priority over this summary. NHS: dexamethasone adverse effects.

Sudden limb weakness or sensory loss, inability to walk, loss of bladder/bowel control or acute confusion needs immediate emergency assessment. Spinal cord compression is one possible serious cause. Tell the service you have myeloma. NHS: myeloma symptoms.

CAR-T can cause dangerous cytokine release, with fever, low blood pressure, rapid heartbeat or breathing difficulty. Follow the cellular-treatment team’s emergency instructions immediately for these symptoms rather than waiting for a routine review. NCI: T-cell transfer and CAR-T.

Report new numbness, tingling or nerve pain to the team immediately; neuropathy can require treatment reassessment. NICE NG35: myeloma recommendations.

Interactions: steroids, blood testing, procedures and complementary products

The pharmacist should check dexamethasone against the full medicine list, including warfarin, diuretics, certain antibiotics or antifungals, epilepsy medicines, NSAID painkillers and HIV medicines. Vaccination plans also need review. Herbal-product safety is not reliably established by the word natural. These are reasons for a medicine check, not instructions to stop prescribed treatments yourself. NHS: dexamethasone interactions.

Food, herbs and supplements can alter how particular cancer medicines are processed or add unwanted effects. Give the team product names and ingredient lists, including nonprescription pain remedies and powders. A compatibility statement for one treatment cannot establish safety with another combination. The review should cover planned changes as well as products already being used. NCI: food and supplement interactions.

Daratumumab-based treatment can interfere with blood crossmatching. Before a transfusion, tell the receiving service which treatment you have had so it can coordinate with hematology. FDA: November 2025 high-risk smouldering approval.

Who needs extra assessment: frailty, organ function, pregnancy and fertility

NICE advises against using age or the degree of kidney impairment alone to decide suitability for a first autologous transplant. Assessment includes frailty, performance and other illnesses. Its diagnostic guidance also warns that a single electrophoresis, immunofixation, light-chain or urine test cannot by itself exclude myeloma. These are dated care principles, not a complete current drug-access list. NICE NG35: myeloma recommendations.

Lenalidomide illustrates why precautions depend on the actual medicine: its dated label contraindicates pregnancy and warns about fetal harm, low blood counts and venous or arterial clots. The prescriber manages the applicable pregnancy-prevention and monitoring requirements. Tell the team immediately about possible pregnancy or serious symptoms; do not borrow another person’s cancer medicine or construct your own protective regimen. BMS/Celgene: dated lenalidomide label.

High-dose chemotherapy and transplant preparation can damage sperm production. If future biological children matter to you, discuss fertility preservation before starting treatment, including sperm banking when appropriate. Reduced fertility does not guarantee that pregnancy cannot occur; ask for the treatment-specific contraception plan and its duration. NCI: male fertility and cancer care.

Chemotherapy and transplant conditioning can damage ovarian function and may cause temporary or permanent fertility changes. Discuss reproductive plans and specialist referral before treatment where feasible. Preservation options and the safety of any delay depend on the individual situation; neither age nor a public treatment description settles that decision. NCI: female fertility and cancer care.

Clinician-led use and follow-up: a written plan for changing disease

A myeloma multidisciplinary team can involve hematology, specialist nurses, pharmacy and services for renal, spinal, orthopedic or other problems. Ask who coordinates your care and which number is available when you are unwell. Bring medication and symptom questions to the service; complex supportive needs should not be left to separate, unconnected appointments. CUH: specialist myeloma service.

Keep the diagnosis, pathology/genetic reports, protein measurements, scan results and treatment dates together. Ask the team to explain which marker it follows, the purpose of the next treatment phase, the reason for each supportive medicine and when a new symptom should trigger contact. Confirm who organizes the next appointment and what to do if it is missed.

There is no safe universal cycle, tablet dose, supplement schedule or transplant recovery calendar to copy from this guide. The treating team should give written instructions for the exact prescription, monitoring and urgent contact. If the plan is unclear, resolve it with the service before making a change based on an online regimen.

Animal and laboratory evidence: mechanisms are not a human prescription

A substance can change a plasma-cell pathway in a dish or animal without producing safe, meaningful benefit in people. Human research needs an appropriate population, safety monitoring and outcomes that matter to patients. A mechanism or laboratory response cannot establish a dose, replace standard care or justify an unregulated product marketed as a myeloma treatment. NCI: human research phases.

Ask what was tested, in whom, against which comparison and with which funding. Laboratory findings remain hypothesis-generating here. Sponsorship and method quality are recorded separately; public hosting or a regulatory decision does not convert maker-supported outcomes into independent research.

Funding and source roles

The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.

Frequently asked questions

Is multiple myeloma the same as a bone cancer? It is a blood cancer of plasma cells in marrow that can affect bones and other organs, rather than simply a tumor arising from bone tissue. NHS: myeloma definition.

Can myeloma occur without a large measurable M protein? Yes. Light-chain and nonsecretory patterns change what can be measured; the team uses appropriate tests rather than one protein result. CUH: myeloma and protein subtypes.

Does everyone with myeloma need immediate treatment? No. Some initially have planned monitoring; the exact diagnosis, disease features, symptoms and health determine the decision. NHS: myeloma treatment.

Is a solitary plasmacytoma the same as multiple myeloma? No. It is localized; evaluation for additional marrow or other disease determines the pathway. NCI: plasma-cell neoplasm patient PDQ.

Who should I contact between myeloma appointments? Use the hematology or acute-oncology contact plan provided by your service, especially when unwell. Ask for the urgent number before leaving clinic. CUH: specialist myeloma service.

Can supplements cure multiple myeloma? No replacement cure is established here. Discuss products with the team and avoid delaying treatment. NCCIH: cancer and complementary approaches.

Sources and funding notes

Reviewed 4 October 2026. This is an adult multiple-myeloma overview; separate precursor, localized-tumor and rare-disorder guides remain open in the scope record. Institutional finance, personal contracts and original-trial sponsorship are distinct. Source dates, draft-stage documents and access limits are preserved in the table. Clinical guidance is attributed; manufacturer-sponsored efficacy is excluded from an independent verdict. No universal transplant age cutoff, monitoring interval, personal regimen or survival prediction is supplied. Archived safety documents do not replace the current prescription and service instructions. Source totals include complete linked prose, FAQ questions, profiles/references and reserves for unlinked evidence/notes.

1. NHS: myeloma definition — Adult plasma-cell blood cancer and individualized care.
2. NHS: myeloma symptoms — Bone pain, fatigue, thirst and emergency neurological symptoms.
3. NHS: myeloma investigation — Blood/urine, marrow and imaging assessment; no waiting-time promise.
4. NHS: myeloma treatment — Individualized combinations, local bone care and monitoring.
5. NHS: myeloma risk factors — MGUS/family/age context; no individual cause or prevention claim.
6. NCI: plasma-cell neoplasm patient PDQ — MGUS/plasmacytoma boundaries; older blanket smouldering and age-cutoff claims excluded.
7. NCI: professional plasma-cell PDQ — Marrow, monoclonal proteins, genetics and staging context; no independently ranked drug result.
8. CUH: myeloma and protein subtypes — Light-chain/nonsecretory distinction; no quantitative prognosis.
9. CUH: specialist myeloma service — Multidisciplinary support and urgent contact planning; local logistics not universal.
10. CUH: marrow aspiration and core biopsy — Sampling and bleeding/medicine assessment; fixed drug holds excluded.
11. CUH: selected myeloma telephone follow-up — Selected monitoring/maintenance patients remain under their consultant; no universal interval.
12. NICE NG35: myeloma recommendations — Diagnostic exclusion limits and transplant fitness; old drug-access list not adopted.
13. Rajkumar: August 2026 myeloma clinical review — Myeloma-defining events only; regimen preferences, survival estimates and sponsored outcomes excluded.
14. NCI: blood stem-cell transplantation — High-dose treatment versus blood-cell recovery; autologous/donor distinction.
15. NCI: T-cell transfer and CAR-T — Specialist cell collection/manufacture and cytokine-release safety; dated therapy count excluded.
16. FDA: November 2025 high-risk smouldering approval — Exact adult high-risk indication and crossmatching precaution only; AQUILA outcome estimates excluded.
17. CRUK: bone-drug jaw complications — Dental coordination and urgent jaw-symptom reporting; no incidence estimate or drug-hold regimen.
18. NHS: dexamethasone adverse effects — Blood-sugar, mood/sleep and infection precautions; no dose threshold.
19. NHS: dexamethasone interactions — Drug/vaccine and herbal disclosure; no personal medicine changes.
20. BMS/Celgene: dated lenalidomide label — Pregnancy, clot and blood-count cautions only; dose, efficacy and numerical adverse-event claims excluded.
21. NCI: nutrition and appetite — Weight/intake and dietitian assessment, no universal renal diet.
22. NCI: cancer fatigue — Assessment of contributing causes and guided activity.
23. NCI: infection during treatment — Dated urgent infection precautions; personal emergency instructions prevail.
24. NCI: palliative care — Concurrent symptom, emotional and practical care.
25. NCI: food and supplement interactions — Drug-specific interactions; original editor/trial finances unclosed.
26. NCI: male fertility and cancer care — Pre-treatment preservation and contraception discussion.
27. NCI: female fertility and cancer care — Conditioning-related fertility injury and specialist assessment.
28. NCI: clinical trial participation — Research consent, eligibility and uncertain personal benefit.
29. NCI: human research phases — Preclinical mechanisms versus meaningful human outcomes.
30. NCI budget — Institutional finance only; not treatment efficacy or author clearance.
31. NCI Gift Fund and contributions — Additional institutional funding route and headquarters; no page allocation inferred.
32. NCI website editorial process — Editorial process only; not an efficacy study.
33. PDQ editorial boards and conflicts — PDQ process and financial limits; PDQ summaries are not formal clinical guidelines.
34. NHS national website content policy — National website funding/editorial policy, not hospital accounts or current author contracts.
35. NCCIH FY2025 congressional justification — Dated institutional route only; no current expenditure total or private-gift exclusion.
36. NCCIH: cancer and complementary approaches — Dated replacement/delay and supplement-interaction safety context; no independent product efficacy verdict.
37. CUH: FY2025–26 audited accounts — Provider revenue only; not leaflet contributor or myeloma-trial clearance.
38. NICE: FY2025–26 audited accounts — Institutional finance only; dated guideline development disclosed separately.
39. CRUK: FY2025–26 own financial summary — Charity revenue route only; no jaw-page contributor or trial clearance.
40. NG35: August 2015 draft development finance — Development provenance only; draft treatment recommendations not adopted.
41. NG35: dated committee interests — Named committee provenance only; no sponsor-supported trial result adopted.
42. Seifter: own clinical-practice biography — Reviewer identity/role only; promotional care-quality claims excluded.
43. Greenspring: oncology insurance/payment routes — Clinical-service interest, not proof of a drug-company or PDQ payment.
44. Seifter: February 2026 course declaration — Named lead’s dated declaration only; all course treatment/efficacy claims excluded.
45. ACP: February 2026 meeting program — Dates and named Seifter talk only; no inference of manufacturer sponsorship.
46. NCI: CA168762 grant identity — Cross-check of one acknowledged grant; clinical/outcome synopsis excluded.
47. AQUILA: sponsor-submitted trial registry — Sponsor provenance only; all progression/survival comparisons excluded.
48. FDA: dated FY2026 budget request — Institutional finance only; no efficacy inference or current enacted-total claim.
49. FDA: prescription-drug user-fee route — Funding route and institutional location only; no causal bias or product outcome inferred.

Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.